{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:56:43Z","timestamp":1779886603293,"version":"3.53.1"},"reference-count":24,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Luminescence"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Avapritinib (AVP) was the first precision drug to be approved by the US Food and Drug Administration (FDA) in 2020 for patients suffering from metastatic gastrointestinal stromal tumors (GISTs) and progressive systemic mastocytosis. The analysis of AVP in pharmaceutical tablets and human plasma was then carried out using a fast, efficient, sensitive, and simple fluorimetric method using a fluorescamine reagent. The procedure is based on the interaction between fluorescamine as a fluorogenic reagent and the primary aliphatic amine moiety in AVP using borate buffer solution at pH\u00a08.8. The produced fluorescence was measured at 465\u2009nm (Excitation at 395\u2009nm). The calibration graph's linearity range was discovered to be 45.00\u2013500.0\u00a0ng\u2009mL<jats:sup>\u22121<\/jats:sup>. Utilizing the International Council for Harmonization (ICH) and US\u2010FDA recommendations, the research technique was validated and bioanalytically validated. The proposed approach was effectively employed for determining the stated pharmaceuticals in plasma with a high percentage of recovery ranging from 96.87 to 98.09 and pharmaceutical formulations with a percentage of recovery equal to 102.11%\u2009\u00b1\u20091.05%. In addition, the study was extended to a pharmacokinetic study of AVP with 20 human volunteers as a step for AVP management in therapeutic cancer centers.<\/jats:p>","DOI":"10.1002\/bio.4550","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T06:50:25Z","timestamp":1688712625000},"page":"1632-1638","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Applicability of fluorescamine as a fluorogenic reagent for highly sensitive fluorimetric analysis of the tyrosine kinase inhibitor (avapritinib) in pharmaceuticals and biological samples"],"prefix":"10.1002","volume":"38","author":[{"given":"Roshdy E.","family":"Saraya","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy Port Said University  Port Said Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baher I.","family":"Salman","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy Al\u2010Azhar University, Assiut Branch  Assiut Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser F.","family":"Hassan","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy Al\u2010Azhar University, Assiut Branch  Assiut Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed I.","family":"Hassan","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy Al\u2010Azhar University, Assiut Branch  Assiut Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shymaa Abdelsattar","family":"Refaat","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry and Molecular Diagnostics Department, National Liver Institute Menoufia University  Shibin Elkom Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9958-4290","authenticated-orcid":false,"given":"Hany A.","family":"Batakoushy","sequence":"additional","affiliation":[{"name":"Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy Menoufia University  Shebin Elkom Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1959315"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01275-2"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24553"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00168-6"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1979.tb03017.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2021.103152"},{"key":"e_1_2_7_8_1","first-page":"1834","volume":"9","author":"Singh T. G.","year":"2020","journal-title":"World J Pharm Pharm. Sci."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2018.10.037"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/bio.4223"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/bio.4291"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1039\/D2RA02241A"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10895-022-02979-2"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10895-022-03128-5"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/bio.4431"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/bio.3292"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2015.12.012"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-022-00849-3"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2018.12.018"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1039\/D0RA07960J"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.298"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2005.02.037"},{"key":"e_1_2_7_23_1","unstructured":"FDA\u2010Approved Drug Products: Avapritinib Oral Tablets."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e23526"},{"key":"e_1_2_7_25_1","unstructured":"United States Pharmacopeial Convention (905) Uniformity of Dosage Units. Stage 6 Harmonization.2011 3 4."}],"container-title":["Luminescence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bio.4550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T13:38:23Z","timestamp":1759930703000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bio.4550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1002\/bio.4550"],"URL":"https:\/\/doi.org\/10.1002\/bio.4550","archive":["Portico"],"relation":{},"ISSN":["1522-7235","1522-7243"],"issn-type":[{"value":"1522-7235","type":"print"},{"value":"1522-7243","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"2023-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}